降脂胶囊对老年冠心病血脂异常患者的调脂及改善血管内皮功能的研究
|
摘要
目的：通过观察(中药制剂)降脂胶囊对老年冠心病血脂异常患者的血脂及炎性因子的影响,探讨其调脂及改善血管内皮功能的作用与机制。
方法：随机抽取200例老年冠心病合并血脂异常患者,按照随机平行对照法的原则分为4组,即辛伐他汀低剂量组(A组)、标准剂量辛伐他汀组(B组)、单纯降脂胶囊组(C组)、中西医结合组(D组),各50例。分别予以A组辛伐他汀10mg qd; B组辛伐他汀20mg qd; C组降脂胶囊4粒tid; D组辛伐他汀10mg qd+降脂胶囊4粒tid。4组连续用药8周,用药前后分别抽取静脉血留存血清备检。进行血常规,尿常规,大便常规,肝、肾功能,ECG等安全性检测以及治疗前后血清TC、TG、HDL-C、LDL-C和CRP、Hey、vWF、NO、ET的含量的测定。
结果：与治疗前相比,降脂胶囊可以降低患者血清TG、TC、LDL-C、Hey、vWF、CRP、ET的含量,提高血清HDL-C、NO的含量(P<0.05)；改善患者血清TG、HDL-C、Hey、vWF的作用优于标准剂量辛伐他汀(P<0.05)；改善血清CRP、ET、NO的作用等同标准剂量辛伐他汀；降低患者血清TC、LDL-C作用等同小剂量辛伐他汀组。降脂胶囊联合小剂量辛伐他汀在改善TG、TC、HDL-C、LDL-C和CRP、Hey、vWF、NO、ET的方面,疗效优于其余三组(P<0.05)。此外,降脂胶囊联合小剂量辛伐他汀的安全性优于标准剂量辛伐他汀组,对大于60岁的老年患者有良好的耐受性。
结论：降脂胶囊能够降低老年冠心病合并血脂异常患者的血清TC、TG、LDL-C和CRP、Hey、 vWF、ET的水平,提高HDL-C、NO的水平；降脂胶囊联合小剂量辛伐他汀调脂效果及改善血管内皮功能更显著,是临床老年冠心病患者安全有效的调脂治疗方案。
Objective:. To explore the effect and mechanism of jiangzhi capsules in regulating blood lipids and improving vascular endothelial function by observing the impact of jiangzhi capsules on blood lipids and inflammatory cytokines in elderly patients with coronary heart disease and dyslipidemia.
Methods:200elderly patients with coronary heart disease and dyslipidemia were randomly divided into four groups according to the principles of randomized controlled method which include low dose simvastatin group (group A, simvastatin10mg qd), conventional-dose simvastatin group (group B, simvastatin20mg qd), jiangzhi capsules alone group (group C, jiangzhi capsules4tid) and the integrative medicine group (group D, jiangzhi capsules4tid and simvastatin10mg qd),50cases in each group. Venous blood were extracted and retained before and after8weeks'treatment respectively for preparing to be tested.Levels of serum lipids profile such as total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) and levels of serum inflammatory cytokines such as c-reactive protein (CRP), homocysteine (Hey), Von Willebrand factor (vWF), nitric oxide (NO) and endothelin (ET)were measured and compared. Other security data such as blood routine, urine routine, stool routine, liver function,renal function and ECG were also been concerned. Results:Compared with before treatment, jiangzhi capsules can significantly reduce levels of serum TC, TG, LDL-C, Hey, vWF and ET, increase levels of serum HDL-C and NO(P <0.05). Jiangzhi capsule alone can significantly improve levels of serum TG, HDL-C、Hey、and vWF, which better than that of conventional-dose simvastatin group (P<0.05). The efficiency improvement of serum CRP, ET and NO in jiangzhi capsule alone group is equivalent to that of standard doses of simvastatin group.The effect of jiangzhi capsule alone on reducing levels of serum TC, LDL-C is also equivalent to that of low dose simvastatin group.Jiangzhi capsules combined with low dose simvastatin were more effective than the other three groups in the improvement of levels of serum TG, HDL-C, LDL-C,CRP, Hey, vWF, NO and ET(P<0.05). In addition, the safety of jiangzhi capsule combined with low dose simvastatin is better than that of conventional dose simvastatin group, which showed well tolerated by elderly patients more than60years of age.
Conclusion:Jiangzhi capsules can reduce levels of serum TC, TG, LDL-C and levels of serum inflammatory cytokines such as CRP, Hcy, vWF and ET, increase levels of serum HDL-C and NO in elderly patients with coronary heart disease and dyslipidemia. The effect of jiangzhi capsules combined with low dose simvastatin in regulating blood lipids and in improving vascular endothelial function is so more significant that it may be a safe and effective clinical treatment programs in regulating blood lipids of elderly patients with coronary artery disease.
方法：随机抽取200例老年冠心病合并血脂异常患者,按照随机平行对照法的原则分为4组,即辛伐他汀低剂量组(A组)、标准剂量辛伐他汀组(B组)、单纯降脂胶囊组(C组)、中西医结合组(D组),各50例。分别予以A组辛伐他汀10mg qd; B组辛伐他汀20mg qd; C组降脂胶囊4粒tid; D组辛伐他汀10mg qd+降脂胶囊4粒tid。4组连续用药8周,用药前后分别抽取静脉血留存血清备检。进行血常规,尿常规,大便常规,肝、肾功能,ECG等安全性检测以及治疗前后血清TC、TG、HDL-C、LDL-C和CRP、Hey、vWF、NO、ET的含量的测定。
结果：与治疗前相比,降脂胶囊可以降低患者血清TG、TC、LDL-C、Hey、vWF、CRP、ET的含量,提高血清HDL-C、NO的含量(P<0.05)；改善患者血清TG、HDL-C、Hey、vWF的作用优于标准剂量辛伐他汀(P<0.05)；改善血清CRP、ET、NO的作用等同标准剂量辛伐他汀；降低患者血清TC、LDL-C作用等同小剂量辛伐他汀组。降脂胶囊联合小剂量辛伐他汀在改善TG、TC、HDL-C、LDL-C和CRP、Hey、vWF、NO、ET的方面,疗效优于其余三组(P<0.05)。此外,降脂胶囊联合小剂量辛伐他汀的安全性优于标准剂量辛伐他汀组,对大于60岁的老年患者有良好的耐受性。
结论：降脂胶囊能够降低老年冠心病合并血脂异常患者的血清TC、TG、LDL-C和CRP、Hey、 vWF、ET的水平,提高HDL-C、NO的水平；降脂胶囊联合小剂量辛伐他汀调脂效果及改善血管内皮功能更显著,是临床老年冠心病患者安全有效的调脂治疗方案。
Objective:. To explore the effect and mechanism of jiangzhi capsules in regulating blood lipids and improving vascular endothelial function by observing the impact of jiangzhi capsules on blood lipids and inflammatory cytokines in elderly patients with coronary heart disease and dyslipidemia.
Methods:200elderly patients with coronary heart disease and dyslipidemia were randomly divided into four groups according to the principles of randomized controlled method which include low dose simvastatin group (group A, simvastatin10mg qd), conventional-dose simvastatin group (group B, simvastatin20mg qd), jiangzhi capsules alone group (group C, jiangzhi capsules4tid) and the integrative medicine group (group D, jiangzhi capsules4tid and simvastatin10mg qd),50cases in each group. Venous blood were extracted and retained before and after8weeks'treatment respectively for preparing to be tested.Levels of serum lipids profile such as total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) and levels of serum inflammatory cytokines such as c-reactive protein (CRP), homocysteine (Hey), Von Willebrand factor (vWF), nitric oxide (NO) and endothelin (ET)were measured and compared. Other security data such as blood routine, urine routine, stool routine, liver function,renal function and ECG were also been concerned. Results:Compared with before treatment, jiangzhi capsules can significantly reduce levels of serum TC, TG, LDL-C, Hey, vWF and ET, increase levels of serum HDL-C and NO(P <0.05). Jiangzhi capsule alone can significantly improve levels of serum TG, HDL-C、Hey、and vWF, which better than that of conventional-dose simvastatin group (P<0.05). The efficiency improvement of serum CRP, ET and NO in jiangzhi capsule alone group is equivalent to that of standard doses of simvastatin group.The effect of jiangzhi capsule alone on reducing levels of serum TC, LDL-C is also equivalent to that of low dose simvastatin group.Jiangzhi capsules combined with low dose simvastatin were more effective than the other three groups in the improvement of levels of serum TG, HDL-C, LDL-C,CRP, Hey, vWF, NO and ET(P<0.05). In addition, the safety of jiangzhi capsule combined with low dose simvastatin is better than that of conventional dose simvastatin group, which showed well tolerated by elderly patients more than60years of age.
Conclusion:Jiangzhi capsules can reduce levels of serum TC, TG, LDL-C and levels of serum inflammatory cytokines such as CRP, Hcy, vWF and ET, increase levels of serum HDL-C and NO in elderly patients with coronary heart disease and dyslipidemia. The effect of jiangzhi capsules combined with low dose simvastatin in regulating blood lipids and in improving vascular endothelial function is so more significant that it may be a safe and effective clinical treatment programs in regulating blood lipids of elderly patients with coronary artery disease.
引文
[]The Scandinavian Simvastatin Survival Study Group.Randomised trial of cholesterol lowering in 4 444 patients with coronary heart disease:The Scandinavian Simvastatin Survival Study (4s). Lancet,1994,344: 1383-1389
[2]Shepherd J, Cobbe SM,Ford I, et al.Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.N ENGLj Med,1995,333:1301-1307.
[3]The Long-Term Intervention with Pravastatin in Ischemic Disease(LIPID) Study Goup.Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J MED,1998,5:339:1349-1357
[4]Sacks FM, Pfeffer MA,Moye LA, et al.The effect of pravastatin on coronary events after myocandial infarction in patients with average cholesterol levels.N Engl J Med,1996,335:1001-1009.
[5]李树岩张文琪.高脂蛋白血症临床分型及遗传基因缺陷.中国社区医师,2002,18(18)：13-14
[6]中国成人血脂异常防治指南制定联合委员会.中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5)：390-413.
[7]杨永宗,阮长耿等AS性心血管病基础与临床.北京科学出版社,2004.139-165.
[8]陆宗良,项志敏.血脂异常的治疗.人民卫生出版社,2002.
[9]陆宗良,项志敏.血脂异常的治疗.人民卫生出版社,2002.
[10]林朝,韦红卫.血脂异常与冠心病关系的临床研究进展[J].医学综述,2006；12(10)：626-628
[11]项志敏,叶平,宁田海.全国血脂异常诊断和治疗专题学术研讨会纪要.中华心血管病杂志,1997,25(3)：165-168.
[12]王霞.冠心病与载脂蛋白测定及意义[J].齐鲁医学检验,2004,15(3)：59
[13]Saku K Zhang B, Ohta T, et al. Quantity and function of high density lipoprotein as Imindicator of coronary atherosclerosis[J]. J Am Coil Cardiol,1999,33(2):436-443
[14]LaRosa J,Grundy,Waters D et al.For the Treating to New Targets(TNT) Investigators. Intensivelipid loweing with atorvastatin in patjents with stable coronary disease. N Engl JMed,2005,352(140):1425-1435
[15]Pedersen T,Faergeman O,Kastelein J,et al.High-dose atorvastatin VS usual—dosesimvastatinforsecondary prevention after myocardial infarction. The IDEAL study:arandomized controlledtrial. JAMA,2005,294(1 9):2437-2445
[16]The FIFLD study investigators. Effects of long—term fenofibrate therapy on cardiovascularevents in 9795 people with type 2 diabetes mellitus(the FIFLDstudy):randomizeA contoroUedtrial. Lancet,2005,366(9500): 1849-1861
[17]Cholesterol Treatment Trialists'Collaborators. Efficacy and safety of cholesterol—loweingtreatment: prospective meta-analysis of data from 90056 participants in 14 trials ofstatins. Lancet,2005.366(9493): 1267-1278
[18]Jones PH, Davidson MH, Stein EA,et a 1.Comparison of the efficacy and safety ofrosuvatatin versus atorvastatin simvastatin and pravatatin across doses. Am J Cardiol,2003; 93(1):152-160
[19]Nissen SE, Nicholls SJ, Sipahi J, et al. Effect of very high-intensive statin therapy on regression of coronary the rosclerosis the ASTEROID trial. JAMA,2006; 295(13):1556-1565
[20]Frick MH,Elo O,Haapa K,,et al. south china journal of cardiology [J].2000,6(1)
[21]]Walter DH, Rittig K, Bahlmann FH, et al. Statin therapy accelerates reendothelialization:a novel effect involving mobilization and incorporation of bone marrow—derived endothelial progenitor cells. Circulation.2002; 105:3017-24.
[22]我国成人血脂异常防治指南制定联合委员会.中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5)：390-413
[23]Gouni-Bertholdl, SachinidisA. Possible non-classic intracellar and molecular mechanismof LDL cholesterolaction contributing to the development and progression of atherosclerosis[J]. Currvascpharmacol, 2004; 2(4):363-370.
[24]泽淇,苏伟青,李树裕,等.氧化低密度脂蛋白免疫复合物与细胞因子在冠心病患者外周血中的检测及意义[J].河北医学,2004,10(3)
[25]ShawPX. Rethinking oxidized low-density lipoprotein, its role inathero-genesis and theimmune responses associated with it[J]. Arch immunol ther exp(Warsz),2004; 52(4):225.
[26]Brandes RESchmitz-Winnenthal FH, Feletou M, et al. An endothelium—derived hyperolarizingfactor distinct from NO and prostacyclin is a major endothelium-dependent vasodilator inresistance vessels of wild-type and endothelial NO synthase knockout mice. Pharmacology,2000; 97(17):974
[27]黄云,戴闺柱,冯宗忱.高甘油三脂血症对血管内皮功能的影响[J].中华心血管杂志.2003；31(6)：421-423
[28]Brousseau ME, Schaefer El, Woife ML et a l. Effacts of an inhibitor of cholesteryl estertransfer protein on HDL cholesterol. N Engl J Med.2004; 350:1505-1516
[29]Vita JA;Yeung AC;Winniford M Effect of cholesterol lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease 2000(08)
[30]鲍延熙,郑义,陆惠华,等.冠心病中医辨证分型与冠状动脉及左室造影所见的联系.中西医结合杂志[J],1989,9(2)：74
[31]甘富东黄照河ET、NO和TNF-α在冠心病发病中的关系探讨[J].现代中西医结合杂志,2010,19(18)：28-29
[32]Loree, Kamm RD, Stringfel low RG et al. Effects offibrous capth J ckness On Deak circumferential stress in model atherosclerotiCvesselS. Circ Res,1992,71:850
[33]Ikeda U, Takahashi M, Shimada K. Monocyte-endothelial eell interactionin atherogenesis and thrombosis [J]. Clin Cardiol,1998,21:11
[34]Vanhoutte PM, Shimokawa h. Endothel ium-derived relaxing and contractingfactory [J]. Circularion, 1989,80:1
[35]Angus JA, Cocks TM, Satoh K. Alpha、drenoreceptors and endothelium-dependent relation in canine large arteries[J]. Br JPharmaco.1986,88:767
[36]Tung TC, Cui G Oshima K, Laks H, Sen L. Balanced expression of mitochondrial apoptosis regulatory-proteins correlates with long-term survival of cardiac allografts. Am J Physiol Heart Circ PhysiOl.2003; 285:H2832-41
[37]Murohara T, Asahara T, Silver M, et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest.1998; 101:2567-78.
[38]盂辉,周永红,孙立,等.加味二陈汤治疗高脂血症82例[J].陕硝中医,2004；25(11)：1000-1001
[39]熊文生,曾益红.理脾化痰脾脂片对高脂血症影响的临床研究[J].中国医药学报,2000；5(2)：35.38
[40]宋晓芳.辨证分型治疗高脂血症82例疗效分析[J].中医药学刊,2001,19(5)：478-479
[41]龚一萍宋国平.试论脏腑功能失调与高脂血症形成的相关性
[42]俞亚琴,郭兮华.从血液流变学探讨高脂血.症的痰湿改变[J].辽宁中医杂志.1995,6：241
[43]李玉英,赵燕.健脾益肾化瘀法治疗高脂血症68例[J].中国社区医师,2003；18(3)：37
[44]赵玉敏.调畅气机在治疗高脂血症中的意义[J].中华中医药杂志,2005；20(8)：488-489
[45]从华伟,王忠玉,王玉风.从肝脾论治高脂血症[J].中国中医药,2005；3(1)：53
[46]佟丽娟,高脂血症的病因病机及辨证分型治疗[J].中医药学刊,2002,20(2)：244
[47]黄学敏,党毓起.软化冠脉汤治疗冠心病[J].陕西中医,1999,50(1)
[48]姚春.化痰逐疲降脂汤治疗高脂血症的疗效观察[J].辽宁中医杂志,2001,28(6)：35
[49]钱卫东,庞德成,朱学云,等.高脂血症中医病因病机探讨[J].湖北中医杂志,2001,3(11)：5
[50]熊文生,曾益宏,刘友章,等.理脾化痰降脂片治疗老年高脂血症140例疗效观察[J].新中医2000,32(7)：16
[51]展照双,王加锋.茯苓泽泻汤加味治疗高脂蛋白血症49例[J].北京中医,2004；23(1)：24-26
[52]崔春霞.自拟降脂汤治疗老年高脂血症168例[J].新乡医学院学报,2004,21(5)：394
[53]刘红健 吴国珍.补肾活血法为主治疗高脂血症的临床研究[J].现代中西医结合杂志,2009,18(22)：33-34
[54]贺燕勤.补肾化浊汤治疗高脂血症的临床观察[J].南京中医药大学学学报,2003,19(1)：61
[55]单存妹 陈谭升.补肾化浊法治疗老年高血脂症的体会[J].现代中西医结合杂志2009,18(22)：2698-2702
[56]胡学红,果春雨.祛脂散治疗高脂血症疗效观察[J].中国冶金工业医学杂志,2005；22(4)：496
[57]李绍鸿,宋崎云,降压散治疗原发性高血压并高脂血症的临床观察,云南中医学院学报,1999,22(1)：33
[58]彭勃,张金生.橄榄降脂胶囊治疗高脂血症56例临床观察[J].河南中医,2005；25(2)：31-33
[59]钱亚玲.疏肝降脂方治疗高血脂症的临床观察[J].内蒙古中医药,2011,30(16)：44-45
[60]张建伟 顾勇主.自拟祛脂汤治疗脂肪肝90例[J].陕西中医,2002,23(1)：10-11
[61]冷英.半夏白术天麻汤监床应用体会,辽宁中医学院学报,2001：3(3)：201
[62]杨传印.二术二陈汤治疗痰湿型高脂血症94例[J].河南中医学院学报,2005;20(4)：54-55
[63]曾庆明等,桃仁红花藤治疗无症状性高脂血症43例临床研无新中医2002,34(6)：20
[64]曹枫,粘脂通冲剂治疗高脂、高粘血症的临床研究,河北中医,1998,20(3)：134
[65]龙庆余,从痰瘀辨治高脂血症60例,安徽中医临床杂志,1998,10(1)：20
[66]陈匡等,降脂中药实验临床研究进展,医学综述,2002,8(6)：370
[67]姜佳仓等.中药丹参及大黄实验性高血脂症大LDL受体基因表达的影响,中国病理生理杂志,1993,9(1)：108
[68]闰道广等,槲皮素、芦丁和BHT对低密度脂蛋白氧化修饰的抑制效应,第一军医大学学报,1995,1：24
[69]牛满山,高脂血症临床治疗进展,中国中医药出版社,1991,81
[70]维良,降脂药物研究,天津中医,1986,(1)：34
[71]孟振行等,丹参对家兔实验性动脉粥样硬化预防作用的研究,心肺血管杂志,1995,2：101
[72]黄维良,活血化痰汤治疗高脂血症36例疗效观察,新中医1998,30(9)：16
[73]王利明等.决明子药用研究,中医药学报,1993,8(3)：30
[74]史培圣,首鸟片治疗高脂血症疗效观察,中西医结合杂志,1989,9(8)：484
[75]李宗其,柴胡降血脂疗效观察,中医杂志,1988,(2)：62
[76]龙金江,八十年代以来柴胡及其方剂药理研究,甘肃中医学院学报,1992,(2)：50
[77]永红等,赤芍、尼群地平对家兔实验性动脉粥样硬化病灶的消退作用,临床心血管病杂志,1996.3：164
[78]牛满山,高脂血.症临床治疗进展.中国中医药出版社,1991,81
[79]陈焕清,熊小强,段朝晖,等.复方丹参滴丸对冠心病血管内皮功能的干预及其机制[J].中山大学学报(医学科学版),2009,30(4s)：221-222,228.
[80]李虹,杨红英.丹红注射液对老年不稳定性心绞痛患者的疗效及内皮功能的影响[J].山东医药,2008,48(32)：92-93.
[81]时广容,宫丽鸿,徐琳,等.桃核承气改良方对免血管内膜剥脱术后内皮素和一氧化氮及一氧化氮合酶的影响[J].中国组织工程研究与临床康复,2008,12(20)：3837-3840.
[82]王静,吴时达,闫亚非,等.复方丹参注射液对冠心病患者血管内皮功能及内皮素和一氧化氮合酶基因表达的影响[J].中国动脉硬化杂志,2004,12(5)：585-588.
[83]饶丹,姜红,曾秋棠.黏附分子细胞间黏附分子-1/E-选择素与冠心病[J].心血管病学进展,2005,26(3)：278-281.
[84]王树国,张艳玲.疏血通注射液对冠心病糖尿病病人血浆ET-1,ICAM-1,TNF-α和P-选择素水平的研究[J].中西医结合心脑血管病杂志,2007,5(7)：574-575.
[85]徐立新,李美,张素燕.麝香保心丸对老年冠心病患者血清E-选择素、P-选择素、SICAM-1、 SVCAM-1的影响[J].中药药理与临床,2005,21(1)：54.
[86]Fichtlscherer S, Rosenberger G, Walter DH, etal. Elevated C-reactive protein levels andimpaired endothelial vasoactivity In patients with coronary arterydi sease[J]. Circulation2000:102; 1000-6
[87]Ross R. Atherosclerosis:all inflammatory disease. N Engl Med 1999:340:115-26
[88]Fichtlscherer S, Rosenberger G, Walter DH, etal. Elevated C-reactive protein levels and impaired endothelial vasoactivity In patients with coronary arterydi sease[J]. Circulation2000:102; 1000-6
[89]Ross R. Atherosclerosis:all inflammatory disease. N Engl Med 1999:340:115-26
[90]张思洁,史晏海,张思明,等.内皮功能与高血压靶器官损伤关系的探讨[J].河北医药.2006,28(8)：707
[91]刘俊芳,朱建华.内皮功能障碍、炎症与动脉粥样硬化[J].浙江医学.2005,27(Ⅱ)：875
[92]吴吉凯,何泮,廖蔚茜等.化痰安神熄风法对原发性高血压疗效及C一反应蛋白水平的影响[J].广东医学.2007,28(8)：1350-1351
[93]卫智权.加用降龙汤对原发性高血压肝阳上亢证患者抗炎及降脂作用的疗效观察[J].广西中医药.2007。30(6)：10-12
[94]董旭,陈分乔,梅建强.高血.压病中医辨证分型与C一反应蛋白及白细胞介素一6的关系[J].中国中医急症.2008,17(4)：483
[95]Meade, T. W. Factor Ⅷ. ABO blood group and the incidence of imhaemic heart disease. British Journal ofHaematology,1994; 88.601-607.
[96]Schumacher SeUeflot ISommervoll L, Christensen B, Otterstad JE, Arnescn H., Increased levels of endothelial haemostatic markers in patients withcoronary heart disease. Thrombosis Research,2002; 105(1): 25-31.
[97]Federici AB, Berkowitz SD. Zimmennsa TS, Mannucci PM. Proteolysis ofvon Willebmnd factor after thrombolytic therapy in patients with acute myocardia linfarction. Blood,1992; 79(1):38-44.
[98]Hans Erik B'rtker,Ingerslev J. Attenuation of hypothermia-induced plateletactivation and platelet adhesion to artificial flurfaces in vitro by modification ofhemoglobin to carry S-nitric oxide and polyethylene glyc01. ThrombRes,2000; 100(6):519-28.
[99]Anderson JL. Calquist JF'Muhlestein JB, et al. Evaluation of C-reactiveprotein,an inflammation marker, and infectious serology as risk for coronary arterydisease and myocardial infarction. J Am Coil Cardiol. 1998,32:35-41.
[100]Ridker PM,Hennekens CH, Buring JE, Ri Ri陆N. C-reactive protein and other markers ofinflammation in the prediction ofcardiovascular disease in women. N Engl J Med.2000; 342(12):836-43.
[101]王奇,胨云渡.梁伟雄,等 血瘀证兔模型血管内皮细胞内分泌功能变化及血府运瘀汤作用的影响[J]。中国中跃基础蜃学杂志,1998,4(6)：31
[102]王奇,郑忠.粱伟雄,等血癣证兔模型的组织形态学观察[J]中西医结合杂志基础理沦研究特集.1993,13：306
[103]翟从永 胡建鹏 王键,等三种中药复方对脑缺血再灌注大鼠血浆咖.管性血友病因子和血栓调节蛋白影响的比较研究水平[J]。中国中医急症,2008,17(10)1419-1420
[104]McCulIy KS Vascular pathology of homocyst(e)lnemia:implications for the development of arterioscleosis Am J Pathol 1969; 56(1):111-128
[105]Malinow MR, Bostom AG, Kraus RM, et al Homocyst(e)inc. diet, and cardlovascular diseases A statement for healthcare professionals fmm the nutrition committee, American Heat Association circulation 1999; 99(1)178-182.
[106]Welch G N,upchurch G R,Loscalzo J.Homocysteine,oxidative stress an d vascular disease [J].Hosp Pract,1997,32(6) :81
[107]McCully K S,Carvalho A C.Homocysteine thiolactone,N-homocysteine th iolactonyl retinamide,and platelet aggregation [J].Research communications in c hemical pathology and pharmacology.1987,56(3):349-60.
[108]Stampfer M J,Malinow M R,Willett W C,et al.Promotion of vascul ar smooth muscle cell growth by homocysteine:a link to atherosclerosis [J].Proc Natl Acad Sci USA,1994,291:537-543
[109]来丽萍,张继东,李丽珍,等.益肾活血提取液对同型半胱氨酸所致的兔V S MC s增殖的抑制作用[J].山东大学学报(医学版),2007,10-1011-05
[110]孔丽君.冠心病患者血浆同型半胱氨酸水平与辨证分型相关性研究[J].实用中西医结合临床,2004,(1)：7
[111]张华云,高红旗,等.山楂对冠心病同型半胱氮酸血症的影响[P].中国病理生理杂志舢2,18(11)：1332
[112]杨丁友,段学忠,马路.桃核承气胶囊治疗冠心病高半胱氮酸血症40例[J].中国中西医结合杂志,2002,22(8)：576
[113]安辉,林凯旋,.加减瓜萎薤白半夏汤治疗冠心病高同型半胱氮酸血症40例[J].福建中医药,2005,36(3)： 11
[114]张继东等.益肾活血胶囊对不稳定性心绞痛患者Hcy及ET_TNF_NO的影响[J].第八次全国中西医结合虚症与老年医学学术研讨会论文集
[115]周珊珊,毛拥军,蔡智荣援 丹参酮对老年冠心病患者血清t-PA,PAI-I水平的影响[J].山东医药,2009,49(15)：69-70.
[116]孙新宇.益心通脉方对糖尿病性冠心病患者纤溶系统的干预研究[J].山东中医杂志,2007,26(7)：450-452.
[117]蒋德菊.川芎嗪对缺氧内皮细胞分泌PGI2、ET、NO的影响[J].中医妇幼保健,2007,14(22)：1993-1994.
[118]齐凤军.电针对高脂血症大鼠血浆ET、TAX2、PGI2水平及动脉内皮保护的影响[J].针灸临床杂志,2007,23(6)：44-45.
[119]姜延,侯贵申,王韶兵,等.参乌冠心颗粒剂对冠心病心绞痛患者血清VEGF与IL6的影响[J].中医药学刊,2006,24(9)：1625-1626.
[120]高爱社,沈晓君.葛根素对oxLDL诱导的血管内皮细胞凋亡的防护作用[J]援山东中医杂志, 2008,27(5)：334-335.
[121]接传红,高健生,柴立民.川芎对血管内皮细胞Bcl-2、Caspase-3基因表达的影响[J].中国中医眼科杂志,2007,17(2)：90-92.
[122]接传红,高健生,李卫红援 川芎抗血管内皮细胞凋亡作用的研究[J].中国中医眼科杂志,2005,15(4)：205-207.
[123]汪莲开,赵艳峰援阿魏酸钠对HO2O2诱导的猪髂动脉内皮细胞凋亡的影响[J].湖北民族学院学报·医学版,2008,25(3)：18-21.
[124]杜云,姜希娟,卢斌,等.救心胶囊对缺氧损伤内皮细胞抗氧化损伤能力影响的实验研究[J].中国实用医药,2007,2(4)：13-14,36.
[125]方唯一.血脂异常与冠心病及其调脂治疗[J].医师进修杂志,2004,7(27)：5.
[126]Doser S, Marz W, Reinecke MF, et al. Recommendations for statintherapy in the elderly [J]. Internist(Berl),2004.45(9):1053-1062
[127]Shepherd J, Cobbe SM,Ford I, et al.Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.N ENGLj Med,1995,333:1301-1307.
[128]张旭明,伍伟.辛伐他汀的临床应用与展望[J].中国药学杂志,2000,35(1)：5-7
[129]姜佳仓等.中药丹参及大黄实验性高血脂症大LDL受体基因表达的影响,中国病理生理杂志,1993,9(1)：108
[130]牛满山,高脂血症临床治疗进展.中国中医药出版社,1991,81
[131]吴腾.辛伐他汀不良反应1例.首都医药,2004,14：36
[132]Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis.JAMA,2004,291:1071-1080.
[133]Ross R.The pathogenesis of atheroslerosis:A perspective for the 1990s.Nature,1993,362:801
[134]曾正陪,血管内皮的内分泌功能[J].中华内科杂志,1998,37(2)：77-77
[135]Kinlay S,Rifai N,Libby P,et al.Effect of atorvastatin on Creative protein in patients with acute coronary syndrome:a substudy of the MIRACL trial[J]. Am Coll Cardiol,2002,39(Suppl A):304A
[136]Ansell BJ,Watson KE,Weiss Re,et al.Hs-CRP and HDL effects of statins (CHEST):rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels. A clinical investigation. Heart Dis,2003,5(l):2-7
[137]Luftjohann D, Sigit IJ, Locatelli S, et al. High-dose simvastatin (80 mg/day) decreases plasma concentrations of total homocysteine in patients with hypercholesterolemia. Atherosclerosis,2001,155: 265-266.
[138]Hashimoto M, Akita H. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation,2002,105:E30-E31.
[139]曾武涛,黄润莲,冷秀玉,等.辛伐他汀对冠心病患者血管内皮功能作用的量效关系[J].中国心血管杂志,2007,12(1)：13-16.
[140]Wu J, XiaoY, WangW, eta.l Effects of simvastatin on vasa vasorum and aortic endothelial function in rats[J]. Nan Fang YiKeDaXue Xue Bao,2010,30(2):275-277
[141]李建微,金元哲,孙小强,等.辛伐他汀对高血压病患者血管内皮功能的影响[J].中国现代医学杂志,2009,17(5)：728-730.
[2]Shepherd J, Cobbe SM,Ford I, et al.Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.N ENGLj Med,1995,333:1301-1307.
[3]The Long-Term Intervention with Pravastatin in Ischemic Disease(LIPID) Study Goup.Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J MED,1998,5:339:1349-1357
[4]Sacks FM, Pfeffer MA,Moye LA, et al.The effect of pravastatin on coronary events after myocandial infarction in patients with average cholesterol levels.N Engl J Med,1996,335:1001-1009.
[5]李树岩张文琪.高脂蛋白血症临床分型及遗传基因缺陷.中国社区医师,2002,18(18)：13-14
[6]中国成人血脂异常防治指南制定联合委员会.中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5)：390-413.
[7]杨永宗,阮长耿等AS性心血管病基础与临床.北京科学出版社,2004.139-165.
[8]陆宗良,项志敏.血脂异常的治疗.人民卫生出版社,2002.
[9]陆宗良,项志敏.血脂异常的治疗.人民卫生出版社,2002.
[10]林朝,韦红卫.血脂异常与冠心病关系的临床研究进展[J].医学综述,2006；12(10)：626-628
[11]项志敏,叶平,宁田海.全国血脂异常诊断和治疗专题学术研讨会纪要.中华心血管病杂志,1997,25(3)：165-168.
[12]王霞.冠心病与载脂蛋白测定及意义[J].齐鲁医学检验,2004,15(3)：59
[13]Saku K Zhang B, Ohta T, et al. Quantity and function of high density lipoprotein as Imindicator of coronary atherosclerosis[J]. J Am Coil Cardiol,1999,33(2):436-443
[14]LaRosa J,Grundy,Waters D et al.For the Treating to New Targets(TNT) Investigators. Intensivelipid loweing with atorvastatin in patjents with stable coronary disease. N Engl JMed,2005,352(140):1425-1435
[15]Pedersen T,Faergeman O,Kastelein J,et al.High-dose atorvastatin VS usual—dosesimvastatinforsecondary prevention after myocardial infarction. The IDEAL study:arandomized controlledtrial. JAMA,2005,294(1 9):2437-2445
[16]The FIFLD study investigators. Effects of long—term fenofibrate therapy on cardiovascularevents in 9795 people with type 2 diabetes mellitus(the FIFLDstudy):randomizeA contoroUedtrial. Lancet,2005,366(9500): 1849-1861
[17]Cholesterol Treatment Trialists'Collaborators. Efficacy and safety of cholesterol—loweingtreatment: prospective meta-analysis of data from 90056 participants in 14 trials ofstatins. Lancet,2005.366(9493): 1267-1278
[18]Jones PH, Davidson MH, Stein EA,et a 1.Comparison of the efficacy and safety ofrosuvatatin versus atorvastatin simvastatin and pravatatin across doses. Am J Cardiol,2003; 93(1):152-160
[19]Nissen SE, Nicholls SJ, Sipahi J, et al. Effect of very high-intensive statin therapy on regression of coronary the rosclerosis the ASTEROID trial. JAMA,2006; 295(13):1556-1565
[20]Frick MH,Elo O,Haapa K,,et al. south china journal of cardiology [J].2000,6(1)
[21]]Walter DH, Rittig K, Bahlmann FH, et al. Statin therapy accelerates reendothelialization:a novel effect involving mobilization and incorporation of bone marrow—derived endothelial progenitor cells. Circulation.2002; 105:3017-24.
[22]我国成人血脂异常防治指南制定联合委员会.中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5)：390-413
[23]Gouni-Bertholdl, SachinidisA. Possible non-classic intracellar and molecular mechanismof LDL cholesterolaction contributing to the development and progression of atherosclerosis[J]. Currvascpharmacol, 2004; 2(4):363-370.
[24]泽淇,苏伟青,李树裕,等.氧化低密度脂蛋白免疫复合物与细胞因子在冠心病患者外周血中的检测及意义[J].河北医学,2004,10(3)
[25]ShawPX. Rethinking oxidized low-density lipoprotein, its role inathero-genesis and theimmune responses associated with it[J]. Arch immunol ther exp(Warsz),2004; 52(4):225.
[26]Brandes RESchmitz-Winnenthal FH, Feletou M, et al. An endothelium—derived hyperolarizingfactor distinct from NO and prostacyclin is a major endothelium-dependent vasodilator inresistance vessels of wild-type and endothelial NO synthase knockout mice. Pharmacology,2000; 97(17):974
[27]黄云,戴闺柱,冯宗忱.高甘油三脂血症对血管内皮功能的影响[J].中华心血管杂志.2003；31(6)：421-423
[28]Brousseau ME, Schaefer El, Woife ML et a l. Effacts of an inhibitor of cholesteryl estertransfer protein on HDL cholesterol. N Engl J Med.2004; 350:1505-1516
[29]Vita JA;Yeung AC;Winniford M Effect of cholesterol lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease 2000(08)
[30]鲍延熙,郑义,陆惠华,等.冠心病中医辨证分型与冠状动脉及左室造影所见的联系.中西医结合杂志[J],1989,9(2)：74
[31]甘富东黄照河ET、NO和TNF-α在冠心病发病中的关系探讨[J].现代中西医结合杂志,2010,19(18)：28-29
[32]Loree, Kamm RD, Stringfel low RG et al. Effects offibrous capth J ckness On Deak circumferential stress in model atherosclerotiCvesselS. Circ Res,1992,71:850
[33]Ikeda U, Takahashi M, Shimada K. Monocyte-endothelial eell interactionin atherogenesis and thrombosis [J]. Clin Cardiol,1998,21:11
[34]Vanhoutte PM, Shimokawa h. Endothel ium-derived relaxing and contractingfactory [J]. Circularion, 1989,80:1
[35]Angus JA, Cocks TM, Satoh K. Alpha、drenoreceptors and endothelium-dependent relation in canine large arteries[J]. Br JPharmaco.1986,88:767
[36]Tung TC, Cui G Oshima K, Laks H, Sen L. Balanced expression of mitochondrial apoptosis regulatory-proteins correlates with long-term survival of cardiac allografts. Am J Physiol Heart Circ PhysiOl.2003; 285:H2832-41
[37]Murohara T, Asahara T, Silver M, et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest.1998; 101:2567-78.
[38]盂辉,周永红,孙立,等.加味二陈汤治疗高脂血症82例[J].陕硝中医,2004；25(11)：1000-1001
[39]熊文生,曾益红.理脾化痰脾脂片对高脂血症影响的临床研究[J].中国医药学报,2000；5(2)：35.38
[40]宋晓芳.辨证分型治疗高脂血症82例疗效分析[J].中医药学刊,2001,19(5)：478-479
[41]龚一萍宋国平.试论脏腑功能失调与高脂血症形成的相关性
[42]俞亚琴,郭兮华.从血液流变学探讨高脂血.症的痰湿改变[J].辽宁中医杂志.1995,6：241
[43]李玉英,赵燕.健脾益肾化瘀法治疗高脂血症68例[J].中国社区医师,2003；18(3)：37
[44]赵玉敏.调畅气机在治疗高脂血症中的意义[J].中华中医药杂志,2005；20(8)：488-489
[45]从华伟,王忠玉,王玉风.从肝脾论治高脂血症[J].中国中医药,2005；3(1)：53
[46]佟丽娟,高脂血症的病因病机及辨证分型治疗[J].中医药学刊,2002,20(2)：244
[47]黄学敏,党毓起.软化冠脉汤治疗冠心病[J].陕西中医,1999,50(1)
[48]姚春.化痰逐疲降脂汤治疗高脂血症的疗效观察[J].辽宁中医杂志,2001,28(6)：35
[49]钱卫东,庞德成,朱学云,等.高脂血症中医病因病机探讨[J].湖北中医杂志,2001,3(11)：5
[50]熊文生,曾益宏,刘友章,等.理脾化痰降脂片治疗老年高脂血症140例疗效观察[J].新中医2000,32(7)：16
[51]展照双,王加锋.茯苓泽泻汤加味治疗高脂蛋白血症49例[J].北京中医,2004；23(1)：24-26
[52]崔春霞.自拟降脂汤治疗老年高脂血症168例[J].新乡医学院学报,2004,21(5)：394
[53]刘红健 吴国珍.补肾活血法为主治疗高脂血症的临床研究[J].现代中西医结合杂志,2009,18(22)：33-34
[54]贺燕勤.补肾化浊汤治疗高脂血症的临床观察[J].南京中医药大学学学报,2003,19(1)：61
[55]单存妹 陈谭升.补肾化浊法治疗老年高血脂症的体会[J].现代中西医结合杂志2009,18(22)：2698-2702
[56]胡学红,果春雨.祛脂散治疗高脂血症疗效观察[J].中国冶金工业医学杂志,2005；22(4)：496
[57]李绍鸿,宋崎云,降压散治疗原发性高血压并高脂血症的临床观察,云南中医学院学报,1999,22(1)：33
[58]彭勃,张金生.橄榄降脂胶囊治疗高脂血症56例临床观察[J].河南中医,2005；25(2)：31-33
[59]钱亚玲.疏肝降脂方治疗高血脂症的临床观察[J].内蒙古中医药,2011,30(16)：44-45
[60]张建伟 顾勇主.自拟祛脂汤治疗脂肪肝90例[J].陕西中医,2002,23(1)：10-11
[61]冷英.半夏白术天麻汤监床应用体会,辽宁中医学院学报,2001：3(3)：201
[62]杨传印.二术二陈汤治疗痰湿型高脂血症94例[J].河南中医学院学报,2005;20(4)：54-55
[63]曾庆明等,桃仁红花藤治疗无症状性高脂血症43例临床研无新中医2002,34(6)：20
[64]曹枫,粘脂通冲剂治疗高脂、高粘血症的临床研究,河北中医,1998,20(3)：134
[65]龙庆余,从痰瘀辨治高脂血症60例,安徽中医临床杂志,1998,10(1)：20
[66]陈匡等,降脂中药实验临床研究进展,医学综述,2002,8(6)：370
[67]姜佳仓等.中药丹参及大黄实验性高血脂症大LDL受体基因表达的影响,中国病理生理杂志,1993,9(1)：108
[68]闰道广等,槲皮素、芦丁和BHT对低密度脂蛋白氧化修饰的抑制效应,第一军医大学学报,1995,1：24
[69]牛满山,高脂血症临床治疗进展,中国中医药出版社,1991,81
[70]维良,降脂药物研究,天津中医,1986,(1)：34
[71]孟振行等,丹参对家兔实验性动脉粥样硬化预防作用的研究,心肺血管杂志,1995,2：101
[72]黄维良,活血化痰汤治疗高脂血症36例疗效观察,新中医1998,30(9)：16
[73]王利明等.决明子药用研究,中医药学报,1993,8(3)：30
[74]史培圣,首鸟片治疗高脂血症疗效观察,中西医结合杂志,1989,9(8)：484
[75]李宗其,柴胡降血脂疗效观察,中医杂志,1988,(2)：62
[76]龙金江,八十年代以来柴胡及其方剂药理研究,甘肃中医学院学报,1992,(2)：50
[77]永红等,赤芍、尼群地平对家兔实验性动脉粥样硬化病灶的消退作用,临床心血管病杂志,1996.3：164
[78]牛满山,高脂血.症临床治疗进展.中国中医药出版社,1991,81
[79]陈焕清,熊小强,段朝晖,等.复方丹参滴丸对冠心病血管内皮功能的干预及其机制[J].中山大学学报(医学科学版),2009,30(4s)：221-222,228.
[80]李虹,杨红英.丹红注射液对老年不稳定性心绞痛患者的疗效及内皮功能的影响[J].山东医药,2008,48(32)：92-93.
[81]时广容,宫丽鸿,徐琳,等.桃核承气改良方对免血管内膜剥脱术后内皮素和一氧化氮及一氧化氮合酶的影响[J].中国组织工程研究与临床康复,2008,12(20)：3837-3840.
[82]王静,吴时达,闫亚非,等.复方丹参注射液对冠心病患者血管内皮功能及内皮素和一氧化氮合酶基因表达的影响[J].中国动脉硬化杂志,2004,12(5)：585-588.
[83]饶丹,姜红,曾秋棠.黏附分子细胞间黏附分子-1/E-选择素与冠心病[J].心血管病学进展,2005,26(3)：278-281.
[84]王树国,张艳玲.疏血通注射液对冠心病糖尿病病人血浆ET-1,ICAM-1,TNF-α和P-选择素水平的研究[J].中西医结合心脑血管病杂志,2007,5(7)：574-575.
[85]徐立新,李美,张素燕.麝香保心丸对老年冠心病患者血清E-选择素、P-选择素、SICAM-1、 SVCAM-1的影响[J].中药药理与临床,2005,21(1)：54.
[86]Fichtlscherer S, Rosenberger G, Walter DH, etal. Elevated C-reactive protein levels andimpaired endothelial vasoactivity In patients with coronary arterydi sease[J]. Circulation2000:102; 1000-6
[87]Ross R. Atherosclerosis:all inflammatory disease. N Engl Med 1999:340:115-26
[88]Fichtlscherer S, Rosenberger G, Walter DH, etal. Elevated C-reactive protein levels and impaired endothelial vasoactivity In patients with coronary arterydi sease[J]. Circulation2000:102; 1000-6
[89]Ross R. Atherosclerosis:all inflammatory disease. N Engl Med 1999:340:115-26
[90]张思洁,史晏海,张思明,等.内皮功能与高血压靶器官损伤关系的探讨[J].河北医药.2006,28(8)：707
[91]刘俊芳,朱建华.内皮功能障碍、炎症与动脉粥样硬化[J].浙江医学.2005,27(Ⅱ)：875
[92]吴吉凯,何泮,廖蔚茜等.化痰安神熄风法对原发性高血压疗效及C一反应蛋白水平的影响[J].广东医学.2007,28(8)：1350-1351
[93]卫智权.加用降龙汤对原发性高血压肝阳上亢证患者抗炎及降脂作用的疗效观察[J].广西中医药.2007。30(6)：10-12
[94]董旭,陈分乔,梅建强.高血.压病中医辨证分型与C一反应蛋白及白细胞介素一6的关系[J].中国中医急症.2008,17(4)：483
[95]Meade, T. W. Factor Ⅷ. ABO blood group and the incidence of imhaemic heart disease. British Journal ofHaematology,1994; 88.601-607.
[96]Schumacher SeUeflot ISommervoll L, Christensen B, Otterstad JE, Arnescn H., Increased levels of endothelial haemostatic markers in patients withcoronary heart disease. Thrombosis Research,2002; 105(1): 25-31.
[97]Federici AB, Berkowitz SD. Zimmennsa TS, Mannucci PM. Proteolysis ofvon Willebmnd factor after thrombolytic therapy in patients with acute myocardia linfarction. Blood,1992; 79(1):38-44.
[98]Hans Erik B'rtker,Ingerslev J. Attenuation of hypothermia-induced plateletactivation and platelet adhesion to artificial flurfaces in vitro by modification ofhemoglobin to carry S-nitric oxide and polyethylene glyc01. ThrombRes,2000; 100(6):519-28.
[99]Anderson JL. Calquist JF'Muhlestein JB, et al. Evaluation of C-reactiveprotein,an inflammation marker, and infectious serology as risk for coronary arterydisease and myocardial infarction. J Am Coil Cardiol. 1998,32:35-41.
[100]Ridker PM,Hennekens CH, Buring JE, Ri Ri陆N. C-reactive protein and other markers ofinflammation in the prediction ofcardiovascular disease in women. N Engl J Med.2000; 342(12):836-43.
[101]王奇,胨云渡.梁伟雄,等 血瘀证兔模型血管内皮细胞内分泌功能变化及血府运瘀汤作用的影响[J]。中国中跃基础蜃学杂志,1998,4(6)：31
[102]王奇,郑忠.粱伟雄,等血癣证兔模型的组织形态学观察[J]中西医结合杂志基础理沦研究特集.1993,13：306
[103]翟从永 胡建鹏 王键,等三种中药复方对脑缺血再灌注大鼠血浆咖.管性血友病因子和血栓调节蛋白影响的比较研究水平[J]。中国中医急症,2008,17(10)1419-1420
[104]McCulIy KS Vascular pathology of homocyst(e)lnemia:implications for the development of arterioscleosis Am J Pathol 1969; 56(1):111-128
[105]Malinow MR, Bostom AG, Kraus RM, et al Homocyst(e)inc. diet, and cardlovascular diseases A statement for healthcare professionals fmm the nutrition committee, American Heat Association circulation 1999; 99(1)178-182.
[106]Welch G N,upchurch G R,Loscalzo J.Homocysteine,oxidative stress an d vascular disease [J].Hosp Pract,1997,32(6) :81
[107]McCully K S,Carvalho A C.Homocysteine thiolactone,N-homocysteine th iolactonyl retinamide,and platelet aggregation [J].Research communications in c hemical pathology and pharmacology.1987,56(3):349-60.
[108]Stampfer M J,Malinow M R,Willett W C,et al.Promotion of vascul ar smooth muscle cell growth by homocysteine:a link to atherosclerosis [J].Proc Natl Acad Sci USA,1994,291:537-543
[109]来丽萍,张继东,李丽珍,等.益肾活血提取液对同型半胱氨酸所致的兔V S MC s增殖的抑制作用[J].山东大学学报(医学版),2007,10-1011-05
[110]孔丽君.冠心病患者血浆同型半胱氨酸水平与辨证分型相关性研究[J].实用中西医结合临床,2004,(1)：7
[111]张华云,高红旗,等.山楂对冠心病同型半胱氮酸血症的影响[P].中国病理生理杂志舢2,18(11)：1332
[112]杨丁友,段学忠,马路.桃核承气胶囊治疗冠心病高半胱氮酸血症40例[J].中国中西医结合杂志,2002,22(8)：576
[113]安辉,林凯旋,.加减瓜萎薤白半夏汤治疗冠心病高同型半胱氮酸血症40例[J].福建中医药,2005,36(3)： 11
[114]张继东等.益肾活血胶囊对不稳定性心绞痛患者Hcy及ET_TNF_NO的影响[J].第八次全国中西医结合虚症与老年医学学术研讨会论文集
[115]周珊珊,毛拥军,蔡智荣援 丹参酮对老年冠心病患者血清t-PA,PAI-I水平的影响[J].山东医药,2009,49(15)：69-70.
[116]孙新宇.益心通脉方对糖尿病性冠心病患者纤溶系统的干预研究[J].山东中医杂志,2007,26(7)：450-452.
[117]蒋德菊.川芎嗪对缺氧内皮细胞分泌PGI2、ET、NO的影响[J].中医妇幼保健,2007,14(22)：1993-1994.
[118]齐凤军.电针对高脂血症大鼠血浆ET、TAX2、PGI2水平及动脉内皮保护的影响[J].针灸临床杂志,2007,23(6)：44-45.
[119]姜延,侯贵申,王韶兵,等.参乌冠心颗粒剂对冠心病心绞痛患者血清VEGF与IL6的影响[J].中医药学刊,2006,24(9)：1625-1626.
[120]高爱社,沈晓君.葛根素对oxLDL诱导的血管内皮细胞凋亡的防护作用[J]援山东中医杂志, 2008,27(5)：334-335.
[121]接传红,高健生,柴立民.川芎对血管内皮细胞Bcl-2、Caspase-3基因表达的影响[J].中国中医眼科杂志,2007,17(2)：90-92.
[122]接传红,高健生,李卫红援 川芎抗血管内皮细胞凋亡作用的研究[J].中国中医眼科杂志,2005,15(4)：205-207.
[123]汪莲开,赵艳峰援阿魏酸钠对HO2O2诱导的猪髂动脉内皮细胞凋亡的影响[J].湖北民族学院学报·医学版,2008,25(3)：18-21.
[124]杜云,姜希娟,卢斌,等.救心胶囊对缺氧损伤内皮细胞抗氧化损伤能力影响的实验研究[J].中国实用医药,2007,2(4)：13-14,36.
[125]方唯一.血脂异常与冠心病及其调脂治疗[J].医师进修杂志,2004,7(27)：5.
[126]Doser S, Marz W, Reinecke MF, et al. Recommendations for statintherapy in the elderly [J]. Internist(Berl),2004.45(9):1053-1062
[127]Shepherd J, Cobbe SM,Ford I, et al.Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.N ENGLj Med,1995,333:1301-1307.
[128]张旭明,伍伟.辛伐他汀的临床应用与展望[J].中国药学杂志,2000,35(1)：5-7
[129]姜佳仓等.中药丹参及大黄实验性高血脂症大LDL受体基因表达的影响,中国病理生理杂志,1993,9(1)：108
[130]牛满山,高脂血症临床治疗进展.中国中医药出版社,1991,81
[131]吴腾.辛伐他汀不良反应1例.首都医药,2004,14：36
[132]Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis.JAMA,2004,291:1071-1080.
[133]Ross R.The pathogenesis of atheroslerosis:A perspective for the 1990s.Nature,1993,362:801
[134]曾正陪,血管内皮的内分泌功能[J].中华内科杂志,1998,37(2)：77-77
[135]Kinlay S,Rifai N,Libby P,et al.Effect of atorvastatin on Creative protein in patients with acute coronary syndrome:a substudy of the MIRACL trial[J]. Am Coll Cardiol,2002,39(Suppl A):304A
[136]Ansell BJ,Watson KE,Weiss Re,et al.Hs-CRP and HDL effects of statins (CHEST):rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels. A clinical investigation. Heart Dis,2003,5(l):2-7
[137]Luftjohann D, Sigit IJ, Locatelli S, et al. High-dose simvastatin (80 mg/day) decreases plasma concentrations of total homocysteine in patients with hypercholesterolemia. Atherosclerosis,2001,155: 265-266.
[138]Hashimoto M, Akita H. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation,2002,105:E30-E31.
[139]曾武涛,黄润莲,冷秀玉,等.辛伐他汀对冠心病患者血管内皮功能作用的量效关系[J].中国心血管杂志,2007,12(1)：13-16.
[140]Wu J, XiaoY, WangW, eta.l Effects of simvastatin on vasa vasorum and aortic endothelial function in rats[J]. Nan Fang YiKeDaXue Xue Bao,2010,30(2):275-277
[141]李建微,金元哲,孙小强,等.辛伐他汀对高血压病患者血管内皮功能的影响[J].中国现代医学杂志,2009,17(5)：728-730.